Disease-modifying anti-rheumatic drugs (DMARDs) are essential in managing inflammatory arthritides such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA). As total hip arthroplasty (THA) and DMARD use become more common, it is unclear how DMARD use affects outcomes in this population. This study compared complications and implant survivorship after THA in patients who have inflammatory arthritis who had and did not have DMARD treatment.
Keywords: Anti-Rheumatic Drugs, Arthropathy, Level of Evidence: III, Outcomes, Total Hip Arthroplasty
The Journal of arthroplasty
Journal Article
English
42001906
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.